Home / Central Data Catalog / FRESH-PEF96-EN
central

MELISSE

France, 2008 - 2011
Reference ID
FRESH-PEF96-en
Producer(s)
Anne Lamblin
Metadata
DDI/XML JSON
Created on
Nov 15, 2025
Last modified
Nov 15, 2025
Page views
7
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Study activities
  • Data Access
  • Contacts
  • Metadata production

    • Identification

    Survey ID number

    FRESH-PEF96-en
    Title

    MELISSE
    Country
    Name
    France
    Abstract

    Describe the prophylactic treatment of phlebitis in patients suffering from multiple myeloma and receiving thalidomide or lenalidomide treatment: - Describe the proportion of patients under prophylactic treatment for phlebitis; - Define the importance of low-molecular-weight heparins (LMWH), vitamin K antagonists (VKA) and aspirin, as well as the arrangements for their use in preventing phlebitis. Describe, over a period of 4 and then 8 months, the occurrence of thromboembolic and hemorrhagic events in patients with multiple myeloma who are under thalidomide or lenalidomide treatment, depending on the thromboprophylactic strategy set up upon inclusion
    Kind of Data

    ['Clinical data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary URI
    Oncology health theme
    cim-11 http://id.who.int/icd/entity/1072688797
    Healthcare system determinants: Use of care health determinant
    Healthcare system determinants health determinant
    Keywords
    prophylaxis thalidomide lenalidomide

    Coverage

    Universe

    {
    "level_sex_clusion_I": [
    "Male",
    "Female"
    ],
    "level_age_clusion_I": [
    "Young Adult (19 to 24 years)",
    "Adult (25 to 44 years)",
    "Middle Aged (45 to 64 years)",
    "Aged (65 to 79 years)",
    "Aged, 80 and over (80 years and more)"
    ],
    "level_type_clusion_I": [
    "General population"
    ],
    "level_type_clusion_other": "",
    "clusion_I": "",
    "clusion_E": ""
    }

    Producers and sponsors

    Primary investigators
    Name
    Anne Lamblin
    Producers
    Name Role
    LABORATOIRES LEO (LEO PHARMA) sponsor
    Funding Agency/Sponsor
    Name
    LABORATOIRES LEO (LEO PHARMA)

    Study authorization

    Agency
    Agency name
    CNIL
    CPP

    Sampling

    Sample frame

    Unit Type

    ['Through organizations (health services or institutions, schools, businesses, etc.)']
    Sampling Procedure

    ['Other']

    Survey instrument

    Questionnaires

    Access on specific project only
    Methodology notes

    Observational Study

    Data collection

    Dates of Data Collection
    Start End
    2008 2011
    Time Method

    Longitudinal or cohort study
    Mode of data collection
    • Interview with the participant (including clinical)

    Study activities

    Study activities
    Type
    primary evaluation
    Description
    Health event/morbidity Health event/mortality Health care consumption and services

    Data Access

    Availability Status

    Restricted access

    Contacts

    Contacts
    Name Email
    Anne Lamblin anne.lamblin@leo-pharma.com

    Metadata production

    DDI Document ID

    FRESH-PEF96-en
    Back to Catalog